Edition:
India

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

18.71USD
22 Mar 2017
Change (% chg)

$-0.44 (-2.30%)
Prev Close
$19.15
Open
$18.98
Day's High
$19.14
Day's Low
$18.30
Volume
115,498
Avg. Vol
99,692
52-wk High
$23.75
52-wk Low
$6.02

ZYNE.OQ

Chart for ZYNE.OQ

About

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in... (more)

Overall

Beta: --
Market Cap(Mil.): $245.02
Shares Outstanding(Mil.): 12.79
Dividend: --
Yield (%): --

Financials

BRIEF-Zynerba Pharmaceuticals completes enrollment for ZYN002 in two phase 2 clinical trials for epilepsy and osteoarthritis

* Zynerba Pharmaceuticals announces completion of enrollment for ZYN002 in two Phase 2 clinical trials for epilepsy and osteoarthritis Source text for Eikon: Further company coverage:

13 Mar 2017

BRIEF-Zynerba Pharmaceuticals says estimates that as of Dec. 31 cash and cash equivalents were about $31 mln

* Zynerba Pharmaceuticals Inc - estimates that as of December 31, 2016 cash and cash equivalents were approximately $31.0 million Source text - http://bit.ly/2jp373S Further company coverage:

19 Jan 2017

BRIEF-Zynerba Pharmaceuticals announces proposed public offering of common stock

* Zynerba Pharmaceuticals announces proposed public offering of common stock

19 Jan 2017

BRIEF-Zynerba Pharmaceuticals posts Q3 loss per share of $0.67

* Zynerba Pharma - believes available funds sufficient to develop five phase 3 ready programs, sufficient to fund operations & capital requirements into 2018

14 Nov 2016

BRIEF-Zynerba Pharmaceuticals initiates Star 2 open-label extension clinical trial for ZYN002 CBD gel

* Zynerba Pharmaceuticals Inc says enrollment in Star 1 is continuing and plan to report top line results in first half of 2017

02 Nov 2016

BRIEF-Zynerba provides clinical update for lead development candidates - ZYN001 and ZYN002

* Zynerba Pharmaceuticals Inc - topline results for three phase 2 clinical trials for ZYN002 are on track for 1h17

17 Oct 2016

More From Around the Web

Earnings vs. Estimates